As expected, the efficacy of the CpdA was more significant in the GR-positive/AR-positive cells than in the GR-positive/AR-negative or the GR-negative/AR-positive cells, suggesting its anti-tumor activity via both the GR and the AR pathways. Here, NR3C1 is linked to neoplasm.